Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04411823 · ClinicalTrials.gov registry record · NA
Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction
A NA study of Gastroesophageal Reflux and Sleeve Gastrectomy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT04411823: Recruiting NA study of Gastroesophageal Reflux and Sleeve Gastrectomy, sponsored by Mayo Clinic.
NCT04411823 is a NA study of Gastroesophageal Reflux and Sleeve Gastrectomy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 200 participants, below the 2,880-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04411823, a NA study of Gastroesophageal Reflux and Sleeve Gastrectomy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.
Primary Outcome
Determined by the change in the GERD-Health Related Quality of Life questionnaire score with questions individually scored on a scale of 0-5, combined to determine a total score range of 0-75 where a higher score indicates worse quality of life and increased score would indicate new or worsening GERD.
Conditions Studied
Interventions
- DEVICE EndoFLIP measurement
Study Locations (2)
Florida
- Orlando Health - Orlando
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2028-10 |
| Phase | NA |
What NCT04411823 shows while recruiting
NCT04411823 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,880-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which EndoFLIP measurement is the first listed.
NCT04411823 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04411823 about?
NCT04411823 is a clinical study titled "Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction". Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.
What is the current status of trial NCT04411823?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2021-02-01. Estimated completion is 2028-10.
What conditions does trial NCT04411823 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux, Sleeve Gastrectomy, Bariatric Surgery Complication.
What interventions are being tested in trial NCT04411823?
The interventions under investigation include: EndoFLIP measurement (DEVICE).
Who is sponsoring clinical trial NCT04411823?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04411823 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04411823's enrollment target sits among peer trials
200 11th of 33 higher than 23 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI